Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

The dominance of the US, and its technology companies in particular, has become an accepted feature of global stock markets.

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...

A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.

BBI Solutions Limited ("BBI"), global leader in the development and manufacture of IVD reagents, announces a CEO succession. After 7 years as ...

Hosted by Demy-Colton and EBD Group, Biotech Showcase will return to the Hilton San Francisco Union Square January 13-15, 2025. A virtual event extends access to networking and insights January 21-22, ...

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of America addresses the company’s earnings and more.

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss drug ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...